|
| Scientific Programme |
| |
|
| Scientific Programme | Search Abstract |
| |
|
|
| Congress |
|
Friday, 20 April 2007
Saturday, 21 April 2007
Monday, 23 April 2007
Tuesday, 24 April 2007
Wednesday, 25 April 2007
|
|
|
| |
| Day |
|
| Friday, 20 April 2007 |
| |
| 09:15-09:40 | |
| Key note lecture I - Pharmacogenetics and regulation of human cytochromes |
|
Chair(s):
|
| |
| 09:40-10:05 | |
| Key note lecture II - Non-viral gene delivery |
|
Chair(s):
|
| |
| 10:05-10:30 | |
| Key note lecture III - HIV entry inhibitors: ligand-based design of peptidomimetic CXCR4 antagonists |
|
Chair(s):
|
| |
| Saturday, 21 April 2007 |
| |
| 09:15-09:40 | |
| Key note lecture IV - Peptide mapping of biofluids by multidimensional LC/MALDI-TOF MS |
|
Chair(s):
|
| |
| 09:40-10:05 | |
| Key note lecture V - Gene expression profiling and breast cancer care |
|
Chair(s):
|
| |
| 10:05-10:30 | |
| Key note lecture VI - Mechanism-based PK-PD modelling of drug efficacy and safety: application to (semi)-synthetic opioids |
|
Chair(s):
|
| |
| Monday, 23 April 2007 |
| |
| 08:30-11:15 | |
| The era of personalised health care: Impact on drug discovery and development? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Is gene/protein delivery delivering? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Can ADME and PK be predicted from in silico/in vitro data? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Metabolomics: What are the opportunities for biomarker discovery? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| What benefits does Process Analytical Technology (PAT) bring to the design and assurance of product quality? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| What have we learnt from recent safety cases for new drug development? |
|
Chair(s):
|
| |
| 12:15-13:10 | |
| Keynote presentation 1 |
|
Chair(s):
|
| |
| 12:15-13:10 | |
| Keynote presentation 2 |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Pharmacogenetics at the bedside? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| What will be the impact of cell-based therapy? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Simulation and modelling in drug development improves decisions, saving time and money? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Dirty vs selective drugs in the CNS? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| How will developments in chemical methods sustain pharmaceutical industrial development? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| How effective is the globalisation/ harmonisation ofpharmacovigilance? |
|
Chair(s):
|
| |
| Tuesday, 24 April 2007 |
| |
| 08:30-11:15 | |
| Druggability: A concept that will fill the pipeline? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Drug targeting: How successful are we? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| What is the state-of-the-science in receptor site modelling? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| What’s new in methods of measuring human drug response? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| In silico product development from molecule to man: Dream or reality? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Nutraceuticals: Are new methods of evaluating risk/benefit required? |
|
Chair(s):
|
| |
| 12:15-13:10 | |
| Keynote presentation 1 |
|
Chair(s):
|
| |
| 12:15-13:10 | |
| Keynote presentation 2 |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Drug-drug interactions: Avoid or understand? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| What is the future of smart, feed-back, on-demand drug delivery systems? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| How are disease and PK-PD connected? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Have omics technologies improved the chance for successful drug development? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Are pharmaceutical manufacturing technologies in stagnation? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Are we using the right outcome measures to ascertain patient benefit from drug therapy? |
|
Chair(s):
|
| |
| Wednesday, 25 April 2007 |
| |
| 08:30-11:15 | |
| How to manage drug therapy at the extremes of age? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| How can nanotechnology and materials science solve drug delivery problems? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| How important is genetic and physiological variability in drug transporters? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Systems biology: A driver of drug discovery and development? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| How to engineer desired particle properties for drug delivery? |
|
Chair(s):
|
| |
| 08:30-11:15 | |
| Off-label use of medicines: Abuse or a vehicle for innovation? |
|
Chair(s):
|
| |
| 12:15-13:10 | |
| Keynote presentation 1 |
|
Chair(s):
|
| |
| 12:15-13:10 | |
| Keynote presentation 2 |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Is the patient taking the tablets? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Developing biotech products: What are the challenges and solutions? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Control of intracellular pharmacokinetics: Advantages for drug therapy? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Molecular targeting in cancer chemotherapy? |
|
Chair(s):
|
| |
| 14:15-16:45 | |
| Miniaturisation in analytical methods: Is small always beautiful? |
|
Chair(s):
|
| |
| 14:15-16:30 | |
| Counterfeiting of medicines: Detection and prevention? |
|
Chair(s):
|
